Alvotech Wins FDA Review Acceptance for AVT80 Biosimilar
Reykjavik, Iceland – August 31, 2026 Alvotech announced that the U.S. FDA has accepted for review its Biologics License...
Alvotech
Advertisement
Alvotech Announces FDA Acceptance of AVT16 Biosimilar Application for Entyvio
REYKJAVIK, Iceland, June 8, 2026 Alvotech announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Kashiv BioSciences Moves Closer to Launching XOLAIR Biosimilar in Canada
PISCATAWAY, N.J., June 4, 2026 Kashiv BioSciences has announced a significant regulatory milestone with the validation and acceptance by...
Alvotech Reports Positive PK Data for Entyvio Biosimilar
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
Alvotech Strengthens Biosimilar Growth With $100M Financing
REYKJAVÍK, ICELAND | December 31, 2025 — Alvotech announced it has secured a USD 100 million senior term loan...
Advertisement
